Immunotherapy and chemo before surgery for low rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination treatment (enverolimab plus standard chemotherapy) given before surgery for very low rectal cancer. The goal is to shrink the tumor so much that patients may avoid surgery and keep their rectum, but the study is for those who haven't had treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have been diagnosed with rectal cancer (adenocarcinoma) that is locally advanced (cT3-4N0 or cT1-4N1-2), and the tumor must be very low, within 2 cm of the anal ring.
- You should be in generally good health (ECOG 0-2, ASA I-III), with adequate organ function (e.g., enough white blood cells, platelets, and kidney/liver function).
- You must not have had any prior chemotherapy, radiation, or immunotherapy for this cancer, and no prior pelvic radiation.
- You must not have certain high-risk tumor types (such as poorly differentiated, mucinous, or signet ring cell) or cancer that has spread to distant organs or certain lymph nodes.
- You must be willing to use effective contraception during the study (if applicable), and be able to give informed consent and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining standard chemotherapy and radiation with an immunotherapy drug (QL1706) before surgery for low rectal cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
This trial tests whether giving chemotherapy and an immunotherapy drug before surgery can help shrink rectal cancer tumors and improve outcomes. It is for patients whose tumors are not caused by a specific genetic mismatch repair problem.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests whether people with early- to intermediate-stage low rectal cancer can avoid surgery if their tumor responds well to a full course of chemotherapy and radiation. It starts with brief chemotherapy, then adjusts treatment based on how much the tumor shrinks.
This trial tests a combination of chemotherapy and radiation therapy before surgery for people with mid or low rectal cancer that hasn't spread. The goal is to see if this approach works better than current treatments.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.